🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

19 results for “4D Molecular Therapeutics” Clear

  1. 4D-150 IVT (3E10 vg/eye)

    4D Molecular Therapeutics

    Macular Neovascularization Secondary to Age-Related Macular Degeneration

    phase 3 mab active

    1 trial

  2. 4D-150 IVT (3E10 vg/eye)

    4D Molecular Therapeutics

    Neovascular Age-Related Macular Degeneration (nAMD)

    phase 3 mab active

    1 trial

  3. DIFLUPREDNATE, Eylea 40 mg/mL solution for injection in pre-filled syringe, Eylea 40 mg/mL solution for injection in pre-filled syringe, 4D-150, Eylea 40 mg/mL solution for injection in pre-filled syringe, Eylea 40 mg/mL solution for injection in pre-filled syringe

    4D Molecular Therapeutics

    Macular neovascularization secondary to age-related macular degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  4. 4D-125 IVT Injection

    4D Molecular Therapeutics

    X-Linked Retinitis Pigmentosa

    phase 2 mab active

    1 trial

  5. 4D-150 IVT

    4D Molecular Therapeutics

    Neovascular (Wet) Age-Related Macular Degeneration

    phase 2 mab active

    1 trial

  6. 4D-150 IVT

    4D Molecular Therapeutics

    Diabetic Macular Edema

    phase 2 mab active

    1 trial

  7. 4D-310

    4D Molecular Therapeutics

    Fabry Disease

    phase 2 mab active

    2 trials

  8. 4D-710

    4D Molecular Therapeutics

    Cystic Fibrosis Lung

    phase 2 mab active

    1 trial

  9. Blautix

    4D Molecular Therapeutics

    Irritable Bowel Syndrome

    phase 2 mab completed

    1 trial

  10. MRx-4DP0004

    4D Molecular Therapeutics

    COVID-19

    phase 2 small molecule terminated

    1 trial

  11. MRx0518

    4D Molecular Therapeutics

    Urothelial Carcinoma

    phase 2 small molecule terminated

    1 trial

  12. MRx0518

    4D Molecular Therapeutics

    Oncology

    phase 2 small molecule terminated

    1 trial

  13. 4D-110

    4D Molecular Therapeutics

    Choroideremia

    phase 1 mab active

    1 trial

  14. MRx-4DP0004

    4D Molecular Therapeutics

    Asthma

    phase 1 small molecule terminated

    1 trial

  15. MRx0029

    4D Molecular Therapeutics

    Idiopathic Parkinson Disease

    phase 1 mab terminated

    1 trial

  16. MRx0518

    4D Molecular Therapeutics

    Pancreatic Cancer

    phase 1 small molecule terminated

    1 trial

  17. MRx0518 Capsules

    4D Molecular Therapeutics

    Melanoma

    phase 1 small molecule active

    1 trial

  18. Training with 4D Motion Capture Device

    4D Molecular Therapeutics

    Stroke

    phase 1 other completed

    1 trial

  19. 4D

    4D Molecular Therapeutics

    Dietary Supplementation

    other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources